

In the Specification:

On page 3, line 13 (just prior to the Summary of the Invention), please insert the following:

Brief Description of the Drawings

The invention will now be described in greater detail with reference to the accompanying drawings in which:

Figure 1 shows morphological features of HL-60 cells undergoing apoptosis following treatment with PBox-6;

Figure 2 shows the percentage of apoptosis induced in HL 60 cells by some pyrrolo-1,5-benzoxazepines and other PBR ligands;

Figure 3 shows that PBox-6-induced apoptosis in HL60 cells is dose- and time-dependent and results in DNA fragmentation;

Figure 4 shows that PBox-6 induces apoptosis through activation of caspase 3-like proteases;

Figure 5 shows the disappearance of pro-caspase 3 in HL-60 cells in response to PBox-6 treatment;

Figure 6 shows the accumulation of Cytochrome C in response to PBox-6;

Figure 7 illustrates that N-acetylcysteine or TEMPO pre-treatment does not protect HL-60 cells against PBox-6 induced apoptosis;

Figure 8 shows the induction of apoptosis in Jurkat cells by pyrrolo-1,5-benzoxazepines;

Figure 9 illustrates the lack of involvement of NF κ B in pyrrolobenzoxazepine-induced apoptosis;

Figure 10 illustrates that PBox-6 induces transient activation of JNK in HL-60 cells;

Figure 11 shows that PBox-6 induces apoptosis in normal (neo) CEM cells;

Figure 12 shows that PBox-6 induces apoptosis in Bcl-2 overexpressed CEM cells;

Figure 13 shows the induction of apoptosis in K562 cells by some pyrrolo-1,5-benzoxazepines and other PBR ligands;

Figure 14 shows that PBox-6 induced apoptosis in CML cells is time and dose-dependent;

Figure 15 shows that PBox-6 induces internucleosomal DNA fragmentation in CML cells;

Figure 16 shows the downregulation of BCR-abl in K562 and KYO.1, but not in Lama 84 cells in response to PBox-6 treatment;

Figure 17 shows the results of Cytochrome C western blotting to analyse the effect of PBox-6 on accumulation of Cytochrome C in the cytosol;

Figure 18 shows Cytochrome C is not all non-specifically released from Mitochondria during sample preparation;

Figure 19 shows activation of caspase 3 in K562 and Lama 84 but not KYO.1 cells in response to PBox-6 treatment;

Figure 20 shows that caspase 3 inhibitor, z-DEVD-fmk, fails to protect against PBox-6 induced apoptosis in CML cells;

Figure 21 shows the induction of PARP cleavage in CML and Hela cells following treatment with PBox-6 and PBox-3;

Figure 22 shows that antioxidants fail to protect against PBox-6 induced apoptosis in K562 cells;

Figure 23 shows that PBox-6 alters the tyrosine phosphorylation status of proteins in K562 cells;

Figure 24 shows that pre-treatment of K562 cells with the tyrosine kinase inhibitor, Genistein, prevents protein tyrosine phosphorylation and inhibits apoptosis induced by PBox-6;

Figure 25 shows that Herbimycin A and Tyrophostin reduce, but do not completely inhibit, PBox-6 induced apoptosis in K562 cells;

Figure 26 shows that Etoposide and mitoxanthrone pre-treatment of K562 cells protects against PBox-6 induced apoptosis;

Figure 27 shows that PBox-6 does not induce DNA strand breaks in K562 cells;

Figure 28 shows that pre-treatment of Jurkat cells with ICRF 187 inhibits etoposide induced DNA strand breaks and protects against apoptosis;

Figure 29 shows that pre-treatment of K562 cells with ICRF 187 reduces the level of apoptosis induced by PBox-6;

D. Williams, et al.
USSN 09/506,362
Amendment After Allowance
Page 5

Figure 30 shows that pre-treatment of Jurkat cells with PBox-6 failed to protect against DNA strand breaks or apoptosis induced by etoposide;

Figure 31 shows PBox-6 induces transient activation of JNK in K562 cells;

Figure 32 shows PBox-6 induces activation of JNK in KYO.1 and Lama 84 cells;

Figure 33 shows lack of activation of p38 in K562 cells in response to PBox-6;

Figure 34 shows lack of activation of p42-44 in K562 cells in response to PBox-6;

Figure 35 shows pre-treatment of K562 cells with an inhibitor of Rac 1, lethal toxin, failed to protect against PBox-6 induced JNK activation and apoptosis;

Figure 36 shows that activation of JNK lies upstream of a requirement for Topo II in the pathway by which PBox-6 induces apoptosis in K562 cells; and

Figure 37 shows PBox-6 induces apoptosis in MCF-7 cells.